Literature DB >> 11444868

The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src.

A Steták1, A Lankenau, T Vántus, P Csermely, A Ullrich, G Kéri.   

Abstract

The heptapeptide TT-232 is structurally related to the hypothalamic hormone somatostatin and shows promise as an anticancer drug because of its tumor-specific cytotoxic effects. Apart from the ability to induce apoptosis, the synthetic peptide can trigger an alternative pathway that leads to cell cycle arrest in certain tumor cell systems. We found that pulse treatment with TT-232 blocks the cell cycle G(1)/S transition irreversibly in A431 cells. Investigation of the TT-232 signaling pathway yielded results similar to those reported for somatostatin although its affinity to the somatostatin receptor 1 is significantly reduced. We show that functional protein kinase C (PKC) delta as well as c-Src are necessary mediators of the TT-232 cytostatic effect and we propose a signaling pathway that leads to cell cycle arrest. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444868     DOI: 10.1006/bbrc.2001.5199

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Mitotic activation of protein-tyrosine phosphatase alpha and regulation of its Src-mediated transforming activity by its sites of protein kinase C phosphorylation.

Authors:  Xin-Min Zheng; Ross J Resnick; David Shalloway
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

2.  Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.

Authors:  Cheng-Zhi Qiu; Chuan Wang; Zhong-Xin Huang; Shi-Ze Zhu; You-Yi Wu; Jian-Long Qiu
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

3.  Upregulated expression of SSTR1 is involved in neuronal apoptosis and is coupled to the reduction of bcl-2 following intracerebral hemorrhage in adult rats.

Authors:  Damin Yuan; Jianhong Shen; Yaohua Yan; Xinmin Wu; Aihong Li; Aisong Guo; Yuanyuan Wu; Chengwei Duan; Jiabing Shen; Cuiying Tang; Dongmei Zhang; Yuhong Ji
Journal:  Cell Mol Neurobiol       Date:  2014-07-18       Impact factor: 5.046

4.  Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.

Authors:  Jörg Stirnweiss; Bianka Hartrodt; Gisela Greksch; Uta Stürzebecher; Frank-D Böhmer; Klaus Neubert; Claus Liebmann
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 5.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

6.  Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.

Authors:  B Szende; A Horváth; G Bökönyi; G Kéri
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.